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Abstract
The purpose of this work was to determine whether there are differences in PIK3CA mutation
status and PTEN protein expression between primary and matched metastatic breast tumors as this
could influence patient management. Fifty-micron paraffin sections were used for DNA extraction
and 3-micron slides for immunohistochemistry (IHC) and fluorescent in-situ hybridization (FISH).
ER, PR and HER2 IHC were repeated in a central laboratory for both primary and metastasis.
PTEN levels were assessed by IHC and PI3K pathway mutations detected by a mass
spectroscopy-based approach. Median age was 48 years (range, 30 to 83 years). Tumor subtype
included 72% hormone receptor-positive/HER2-negative, 20% HER2-positive, and less than 7.8%
triple receptor negative. Tissues were available for PTEN IHC in 46 primary tumors and 52
metastases. PTEN was lost in 14 (30%) primary tumors and 13 (25%) metastases. There were 5
cases of PTEN loss and eight cases of PTEN gain from primary to metastasis (26% discordance).
Adequate DNA was obtained on 46 primary tumors and on 50 metastases for PIK3CA analysis.
PIK3CA mutations were detected in 19 (40%) of primary tumors and 21 (42%) of metastases.
There were five cases of PIK3CA mutation loss, and four cases of mutation gain (18%
discordance). There was an increase of the level of PIK3CA mutations in four cases, and decrease
in one from primary to metastasis. There is a high level of discordance in PTEN level, PIK3CA
mutations, and receptor status between primary and metastatic disease that may influence patient
selection and response to PI3K-targeted therapies.
Address for reprints: Ana M. Gonzalez-Angulo, M.D., Department of Breast Medical Oncology, The University of Texas M. D.
Anderson Cancer Center, Unit 1354, 1515 Holcombe Boulevard, Houston, TX 77030-4009; Tel: (713) 792-2817; Fax: (713)
794-4385;, agonzalez@mdanderson.org.
NIH Public Access
Author Manuscript
Mol Cancer Ther. Author manuscript; available in PMC 2012 June 1.
Published in final edited form as:
Mol Cancer Ther. 2011 June ; 10(6): 1093–1101. doi:10.1158/1535-7163.MCT-10-1089.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Keywords
PIK3CA mutations; PTEN loss; Breast Cancer; Metastasis
Introduction
Given the ability of hormone receptors (HR) and HER2 levels to predict response to therapy,
it is currently recommended that they should be determined on every primary invasive breast
cancer. However, changes in receptor status over disease progression and treatment have
been described that could alter response to therapy. Concordance rates between primary
tumors and recurrence site of 71% and 56% have been reported for estrogen receptor (ER)
and progesterone receptor (PR) expression, respectively, and discrepancy rates for HER2
expression between primary tumors and matched metastasis may be as high as 20% (1,2).
Further, in a series of patients with HER2-positive breast cancer treated preoperatively with
trastuzumab, we reported that the HER2 status assessed by gene amplification changed to
negative in over 30% of the cases who had extensive residual disease at the time of surgery
(3). We recently reported that discordance of receptor status between primary and metastatic
disease correlates with survival in patients with breast cancer (4). This suggests that optimal
patient outcomes and responses in clinical trials could potentially be achieved by obtaining
and evaluating tissue from metastatic sites.
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR)
pathway mediates multiple cellular functions critical to tumor initiation, progression and
outcomes, including growth and proliferation, metabolism, motility, migration, invasion,
angiogenesis, survival and autophagy (5). Tight regulation of this pathway is paramount to
ensure that multiple cellular inputs are integrated for appropriate cellular outcomes.
Frequent deregulation and aberrations of this pathway have been implicated not only in
breast cancer development and progression (6), but in breast cancer therapy resistance (7–
10). Thus, multiple drugs targeting the PI3K/Akt/mTOR pathway are in development and in
early clinical trials as mono and combination therapies in breast cancer (6). Our group has
also shown significant changes from primary to metastasis on phosphorylation events that
serve as biomarkers for response to PI3K/Akt/mTOR signaling targeted therapies (48%
discordance on p-Akt and p-4E-BP1) (11). A discordance between the level of potential
biomarkers in primary tumor and metastasis could occur due to alterations in gene
expression, possibly due to different microenvironmental stimuli, from stochastic events
during metastasis, from clonal selection during metastasis or from clonal evolution either at
the primary site or in the metastasis. However, as new targeted therapies enter clinical trials
in the metastatic setting using signatures from the primary tumor for patient selection may
have profound outcome implications if biomarkers are discordant between the primary and
metastatic site(s). PIK3CA mutation and loss of PTEN expression are being pursued as
potential predictors of response to novel PI3K pathway inhibitors. Thus, to optimize patient
selection for PI3K-targeted therapy, it is critical to determine whether mutation status of
PI3K pathway components and PTEN loss in the primary tumor is concordant with the
status of these markers in the metastases.
The objective of this study was to determine whether there are differences in mutation status
of components of the PI3K pathway and in PTEN protein expression between primary and
metastatic tumors.
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Methods
Under a research collaboration between MD Anderson Cancer Center and the Hospital
Clinico Universitario de Valencia, Spain, we located paraffin blocks and corresponding
clinical information of 50 matched pairs of primary breast cancer and biopsies of their
corresponding asynchronous metastasis (distant nodes, skin, liver, lung, and bone). Paraffin
blocks were sectioned. Two 50-micron thick cuts were used for DNA extraction, and 3-
micron slides were used for IHC and florescent in-situ hybridization (FISH). All cases were
reviewed by dedicated breast pathologists. ER, PR and HER2 staining were repeated in a
central lab in both primary and metastatic tumors. FISH analysis was done in all cases that
had 2+ staining by IHC, or if there was a discordant result between the primary tumor and
the metastasis. The institutional review board of both institutions approved the laboratory
studies and chart reviews.
IHC analysis to determine ER (clone SP1) and PR (clone 1E2) status was performed on 3-
μm sections of formalin-fixed, paraffin-embedded tissues, using a Benchmark XT
instrument (Ventana, Tucson, AZ). Both, Allred score (12) and percentage of nuclear
staining were determined. Tumors with moderate to intense nuclear staining of at least 1%
or more (13) or an Allred score equal or greater than 3/8 (12) were considered ER or PR-
positive. IHC analysis for HER2 was performed under similar conditions, using the Pathway
anti-HER-2/neu [4B5] monoclonal antibody (Ventana, Tucson, AZ). FISH analysis was
performed using HER2 FISH Pharm Dx (Dako, Carpinteria, CA) according to the
manufacturer’s instructions. HER2-positive was defined as 3+ receptor over-expression on
IHC staining (strong membranous staining in at least 30% of cells), and/or gene
amplification found on FISH. A gene copy/CEP-17 ratio greater than 2.2 was considered
amplified (14).
PTEN IHC was performed using monoclonal mouse anti-Human PTEN antibody Clone
6H2.1 from Dako at 1:100 dilution. Negative control slides without primary antibody were
included for each staining. Both cytoplasmic and nuclear PTEN staining in the tumor and
non-neoplastic ductal epithelium and stroma were quantified. PTEN staining in the non-
neoplastic normal epithelium, intratumoral and extratumoral stromal cells served as the
internal positive control. Cases in which stromal staining was not observed were considered
inevaluable. PTEN expression level was scored semiquantitatively based on staining
intensity and distribution using the immunoreactive score (IRS) from as following: IRS = SI
(staining intensity) × PP (percentage of positive cells). SI was determined as 0 = negative; 1
= weak; 2 = moderate; and 3 = strong. PP was defined as 0, <1%; 1, 1%–10%; 2, 11%–50%;
3, 51%–80%; and 4, >80% positive cells. Ten visual fields from different areas of each
tumor were used for the IRS evaluation. Tumors with IRS of 0 were considered to have
PTEN loss.
At least 70% tumor nuclear cellularity was confirmed in the samples used for DNA
extraction. DNA was extracted using the QiaAMP microkit (Qiagen Inc. Valencia, CA)
according to manufacture’s instructions. A mass spectroscopy-based approach evaluating
single nucleotide polymorphisms (SNPs) was used to detect known mutations in PIK3CA
(PIK3CA_A1046V, PIK3CA_C420R, PIK3CA_E110K, PIK3CA_E418K,
PIK3CA_E453K, PIK3CA_E542K, PIK3CA_E545K, PIK3CA_F909L, PIK3CA_G1049R,
PIK3CA_G451L456_V, PIK3CA_H1047L, PIK3CA_H1047R, PIK3CA_H1047Y,
PIK3CA_H701P, PIK3CA_K111N, PIK3CA_M1043V, PIK3CA_N345K,
PIK3CA_P539R, PIK3CA_Q060K, PIK3CA_Q546E, PIK3CA_R088Q, PIK3CA_S405F
and PIK3CA_T1025S), AKT1 (AKT1_E17K_G49A, AKT1_G173R_G517C,
AKT1_G173R_G517C), AKT2 (AKT2_E17K_G49A, AKT2_G175R_G523C), and AKT3
(AKT3_E17K_G49K, AKT3_G171R_G511A). Polymerase chain reaction (PCR) and
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extension primers for each gene were designed using Sequenom, Inc. (San Diego, CA)
Assay Design. PCR-amplified DNA was cleaned using EXO-SAP (Sequenom) primer
extended by IPLEX chemistry, desalted using Clean Resin (Sequenom) and spotted onto
Spectrochip matrix chips using a nanodispenser (Samsung). Chips were run in duplicate on a
Sequenom MassArray MALDI-TOF MassArray system. Sequenom Typer Software and
visual inspection were used to interpret mass spectra. Reactions where equal or more than
8% of the resultant mass run in the mutant site in both directions were scored as positive.
The MassArray approach allows quantification of the percent of the DNA present that
demonstrates the PIK3CA mutation, which reflects the fraction of cells with the mutations.
Reactions in which there was more than a 50% increase or decrease in the value of DNA
present that demonstrates the PIK3CA mutation, the mutation score were also reported. In
preliminary work, we directly compared standard Sanger sequencing and the Sequenom
MassARRAY detection on 100 tumor samples. Sanger sequencing showed 11 out of the 100
samples to have PIK3CA mutations. Using the Sequenom method, we detected all of the
PIK3CA somatic mutations expected from Sanger sequencing analysis plus an additional 11
putative mutations. The utility and accuracy of the probes as well as the ability to quantify
aberrations were confirmed with analysis of breast cancer cell lines with known PIK3CA
mutations prior to analyzing patient samples. As demonstrated by mixing experiments using
cells with known mutations, the Sequenom approach can detect a mutation even if it is
present in only 5% of the cell population and can give quantitative information on each
mutation.
Patients were categorized according to their PIK3CA mutation and or PTEN status. Patient
and tumor characteristics were tabulated and compared between the chi-square and the
Fisher test as appropriate. Time to recurrence (TTR) was measured from the date of
diagnosis to the date of first documented local or distant recurrence (metastasis biopsy). The
Kaplan-Meier product limit method was used to estimate the TTR of all patients by
concordant and discordant marker (PIK3CA and/or PTEN) status, and groups were
compared with the log-rank statistic. P-values less than 0.05 were considered statistically
significant; all tests were two-sided. Statistical analyses were carried out using SAS 9.2
(SAS Institute Inc., Cary, NC) and S-Plus 7.0 (Insightful Corporation, Seattle, WA).
Results
Patients were categorized according to breast cancer subtype and their tumor characteristics
are presented in Table 1. Median age was 48 years (range, 30 to 83 years), 58.8% of the
patients were postmenopausal. Seventy-eight percent of the tumors had a ductal histology;
more than 50% had a high nuclear grade and lymphovascular space invasion. Distribution
by tumor subtype included 72.5% hormone receptor-positive and HER2-negative (HR),
19.6% HER2-positive (HER2), and less than 10% triple receptor negative (TNBC). Ninety-
eight percent of patients received systemic chemotherapy with an anthracycline or an
anthracycline/taxane-based regimen (53%). All patients with HR tumors received adjuvant
endocrine therapy. Distant disease free survival was 90 months, (range: 5–210 months).
Initial distribution of the metastatic sites included bone only in 6 (11.8%) patients, visceral
only in 6 (11.8%) patients and bone and visceral in 39 (76.4%) patients. Metastasis tissues
were obtained from at least one metastatic site in all cases, two metastatic sites in seven
cases, and three metastatic sites in one case. The time between obtaining samples of primary
tumor and metastases was 46.5 months, (range from 10 to 229 months). Metastatic samples
were obtained from soft tissue: 17 (28.8%), lymph nodes: nine (15.2%), lung: eight (11.8%),
bone: six (10.2%), liver: three (5.1%), brain: two (3.4%), pleura: two (3.4%), ovary: two
(3.4%), peritoneum: one (1.7%), and bowel: one (1.7%).
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Tissues were available for PTEN IHC in 46 primary tumors and 52 metastases. PTEN loss
was found in 14 (30.4%) of the primary tumors and 13 (25%) of the metastases. There were
no significant differences in the proportion of tumors with PTEN loss between primary
tumors and metastasis, (P=0.708), (Figure 1). Adequate DNA was obtained on all 46
primary tumors and on 50 of the 59 metastases. Mutations in AKT1, AKT2 or AKT3 were not
detected. Mutations in PIK3CA_H1047_A3140 and PIK3CA_E545_G1633 were found in
this sample set. All others tested were not detected. A mutation in PIK3CA was found in 19
(40.4%) of the primary tumors and 21 (42%) of the metastases. Mutations in
PIK3CA_E545_G1633 occurred in only one primary tumor and in one of its corresponding
metastasis. All other PIK3CA mutations occurred at PIK3CA_H1047_A3140. There were no
significant differences in the proportion of tumors with PIK3CA mutations between primary
tumors and metastasis, (P=0.961), (Figure 1).
The results of the frequency of PTEN loss and PIK3CA mutations by tumor subtype are
summarized in Table 2.
When looking at standard of care breast cancer markers (ER, PR and HER2), there were 51
pairs of primary tumors and metastases, samples for two metastatic sites in seven cases, and
three metastatic sites in one case for a total of 59 comparisons. There was a 25.4%
discordance rate from primary to metastasis: four tumors lost ER, seven tumors lost PR and
one tumor lost HER2. Two tumors became PR-positive and one tumor became HER2-
positive in their metastatic sites.
For PTEN analysis, there were 51 pairs of primary tumors and metastases, samples for two
metastatic sites in seven cases, and three metastatic sites in one case for a total of 59
comparisons. Ten slides (9 comparisons) were considered inevaluable due to lack of
adequate tissue. There were five cases of PTEN loss and eight cases of PTEN gain from
primary to metastasis for a 26% discordance rate. When looking at PTEN loss, three of the
five primary tumors were HR-positive and stayed HR-positive in their metastatic sites. One
tumor was HER2-positive and had a PIK3CA mutation in detected in both primary and
metastasis. Interestingly one tumor was a primary TNBC at diagnosis, was found to be HR-
positive at the metastatic site, and also gained a PIK3CA mutation. All these patients
received chemotherapy (anthracycline and taxane-based), and all but the TNBC patient
received adjuvant tamoxifen. When looking at the cases that became PTEN positive, seven
of the eight tumors were HR-positive in both primary and metastases; three of them had a
PIK3CA mutation in both primary and metastases. However, one tumor demonstrated a
significant increase in the number of cells with PIK3CA mutations in the metastatic site. One
tumor classified as HER2-positive in the primary site, became a TNBC at the metastatic site.
All these patients received chemotherapy (anthracycline and taxane-based), and adjuvant
tamoxifen. The patient with the HER2-positive primary tumor that changed to TNBC in the
metastasis did not receive trastuzumab.
In two cases in which there were more than one metastases, there were discordant findings
between the metastases. One primary tumor in which PTEN was lost, PTEN continued to be
lost in the bone biopsy, however, there was PTEN gain (score of 8) in the mediastinal node
metastasis. In a second primary tumor in which PTEN was positive, PTEN continued to be
positive in the liver biopsy, however, there was PTEN loss in the ovary biopsy. Both tumors
had PIK3CA mutations in the primary and all metastatic sites. Figure 2 shows representative
matched cases of primary and metastatic disease including stable positive and negative
staining, and show changes in PTEN levels from absent to gain, and from present to loss.
For PIK3CA mutation analysis, there were 51 pairs of primary tumors and metastases,
samples for two metastatic sites in seven cases, and three metastatic sites in one case for a
total of 59 comparisons. There was insufficient DNA in 13 samples (11 comparisons). There
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were five cases were PIK3CA mutations were detected in the primary tumor but not in the
metastasis, and four cases where PIK3CA mutation was not detected in the primary but was
detected in the metastasis, for an 18% discordance rate. Figure 3 shows a representative case
of a marked increase levels of PIK3CA mutation. There was increase in the fraction of DNA
with the PIK3CA mutation by more than 50% in four cases between the primary and the
metastasis, and a decrease in the percentage of cells with the PIK3CA mutation by more than
50% in one case from primary to metastasis.
When looking at cases where PIK3CA mutation was detected in the primary and not the
metastasis, four tumors were HR-positive, and one was a TNBC. Interestingly from the four
HR-positive tumors, one tumor was found to be HER2-positive at the metastatic site, and
one tumor was found to be a TNBC in the metastatic site. There were no changes in PTEN
IHC. Four these patients received chemotherapy (anthracycline and taxane-based), and
adjuvant tamoxifen, and one patient did not received chemotherapy, but adjuvant letrozole.
There was one case in which the primary tumor had a PIK3CA mutation (69%), the mutation
was detected in a mediastinal metastasis, but with a significant decrease (24%), and where
the mutation was not detected in a liver metastasis. PTEN was lost in the primary and
metastatic samples. This case was a HR-positive tumor that became TNBC in both
metastatic sites and received chemotherapy (anthracycline and taxane-based), and adjuvant
tamoxifen.
When looking at cases where PIK3CA mutations were detected in the metastasis but not the
primary, two of the four tumors were HR-positive; one was HER2-positive and one was a
TNBC. One of the HR-positive tumors became PTEN-positive in the metastasis. The TNBC
became HR-positive in the metastatic site and lost PTEN. Patients with HR-positive tumors
received chemotherapy (anthracycline and taxane-based), and adjuvant tamoxifen. The
patient with the HER2-positive tumor received adjuvat tamoxifen (tumor was ER-positive),
and the patient with TNBC did not receive adjuvant systemic chemotherapy.
When looking at cases with more than 50% changes in the fraction of DNA with the
PIK3CA mutation, all four tumors with increased fractions were HR-positive. One gained
PTEN levels from a score of 0 to 4. All four received chemotherapy (three anthracycline-
based, and one anthracycline and taxane-based), and adjuvant tamoxifen.
Table 3 and Figure 1 summarize the changes in markers between primary and metastatic
breast cancer. Table 4 shows the significant changes in the percentage of the DNA fraction
with PIK3CA mutations in the primary and metastatic tumors.
There were no differences in median TTR in between patients that had discordant tumors
compared to patients that had concordant tumors by PTEN levels and PIK3CA mutation
status: 37 months vs. 40 months, P= 0.922.
The therapy for breast cancer patients is currently different based on hormone receptor and
HER2 expression. The breast cancer subtype was different between the primary and the
metastasis in 4 patients, which would result in a change in therapy based on current
guidelines. For two HR-positive primary tumors: one was a TNBC and lost PTEN in both
metastases, while maintaining a PIK3CA mutation in the primary in one metastatic site, but
with the PIK3CA mutation not being detected in a second metastatic site. One HER2-
positive cancer became TNBC and gained PTEN; and one TNBC became HER2-positive,
which was associated with the detection of a PIK3CA mutation in the metastatic but not the
primary site.
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Discussion
The PI3K/Akt/mTOR signaling pathway is an emerging therapeutic target for cancer
therapy. As a result there is an urgent need to identify robust markers that can determine
pathway activity and likelihood of benefit from pathway targeting therapy. Mutations at the
PIK3CA gene and the levels of PTEN are being studied as possible predictive markers for
PI3K pathway inhibitors. However, it is unknown, if the assessment of these markers in the
primary tumor accurately reflects the status of these markers in metastases arising from the
same tumor. This is particularly important in breast cancer, where the primary tumor is
removed surgically and the target for therapy is usually occult micro-metastases. We report
the results of a systematic evaluation of concordance in PTEN levels and PI3K pathway
mutations in matched primary tumor and metastases. We found that overall, PI3K pathway
aberrations are common, and that half of primary tumors as well as metastases have either
PIK3CA mutations, PTEN loss or both. The overall rates of PIK3CA mutation and PTEN
loss were similar in the primary and matched metastasis. Further PIK3CA and PTEN loss
were found together with approximately the expected frequency indicating that there was
neither co-selection nor mutual exclusion for these events. However, we found marked
discordances in PTEN levels (26%), PIK3CA mutations (18%), and receptor status (25%)
between the primary tumor and metastases. Strikingly, there was both gain and loss of
ability to detect PTEN and PIK3CA mutations between the primary and metastasis
suggesting that at least in terms of PIK3CA and PTEN, metastasis is likely a stochastic event
with metastatic competence not being dependent on aberrations in the PI3K/Akt/mTOR
pathway.
Several studies have addressed the issue of discordance in expression of individual breast
cancer markers (ER, PR and HER2) between primary tumor and recurrence/metastasis, but
discordance rates varied substantially from study to study (1,2,11,15–17). Others have
studied different markers with similar conflicting results. Lacroix et al, looked at the
membrane protein levels of HER2 and epidermal growth factor (EGF) receptor as well as
gene aberrations affecting these oncogenes in human primary and metastatic lesions. Among
57 patients, expression level and gene copy numbers of HER2 or EGF receptor were
similarly altered in the primary tumor and metastatic lesions derived from the same patient
(18). Using IHC or sandwich enzyme immunoassay investigators determine expression
levels of HER2 and p53 proteins in 42 breast cancer samples from 21 patients who
underwent surgery for primary tumors and surgical resection of asynchronous metastases.
ER and PR were also measured by enzyme immunoassay in each case. Although, there was
no difference in the positivity rate of HER2 and p53 expression between the primary tumors
and the metastases, there was 50% discordance in ER and PR expression (19). Using IHC,
Cardoso et al., reported the percentage of discordant biomarker status in the primary tumor
and its metastatic lymph nodes to be 2% for HER2, 6% for p53, 15% for bcl-2, 19% for
topoisomerase II-α, 24% for HSP27 and 30% for HSP70. For the subgroup of patients with
positive biomarkers in the primary tumor, the percentage of discordance was 6% for HER2,
7% for p53, 14% for bcl-2, 19% for HSP70, 21% for topoisomerase II-α and 36% for
HSP27. For the subgroup of patients with positive biomarkers in the lymph nodes, the
percentage of discordance was 9% for bcl-2, 15% for HER2 and p53, 21% for
topoisomerase II-α, 22% for HSP27 and 25% for HSP70 (20).
Previous reports have not compared PI3K pathway mutational status and PTEN levels in
primary tumors and their corresponding metastases. However investigators recently reported
the frequency of PIK3CA mutations in in-situ and invasive breast cancer. They sequenced
exons 9 and 20 of PIK3CA in pure ductal carcinoma in situ (DCIS), DCIS adjacent to
invasive carcinoma, and invasive ductal breast carcinomas. In a subset of cases, both in situ
and invasive areas were analyzed from the same tumor. They found that the frequency of
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PIK3CA mutations was approximately 30% in all three histologic groups, consistent with
previous reports for invasive cancer (21). Interestingly in a third of the cases, in situ and
invasive areas of the same tumor were discordant for PIK3CA status, and in two cases in
which multiple invasive and adjacent in situ areas within the same tumor were analyzed
independently, they detected intratumor heterogeneity for PIK3CA mutations (22). Thus
there appear to be multiple tumor subclones with different mutation status present in primary
tumors. Using IHC, we previously looked at the discordance in the expression of pAkt
(Ser473) and p4E-BP1 (Ser65) between primary breast cancer and matched surgically
resected metastases. We found that most primary breast tumors and metastases expressed
pAkt (76% of each). However of the 23 matched evaluable pairs, 11 (47.8%) had discordant
IHC results. Similarly, although most of the primary and metastatic tumors were positive for
p4E-BP1 (75% and 74%), of the 23 matched evaluable pairs, 8 (47.8%) were discordant
(11).
Our study suggests that PIK3CA mutation status and PTEN levels may differ between
primary tumors and their metastases. We had anticipated that if there were discordances,
these would be consistent with higher PI3K/Akt/mTOR signaling in metastases because of
molecular evolution, therapy exposure/selection and increased metastatic potential of active
pathway clones. Unexpectedly, we found that almost the same proportion of patients had
activating PIK3CA mutations in their primary tumor and not in the metastasis as had
activating mutations in their metastasis but not in the primary. We found similar results
when looking at PTEN levels. The gain and loss frequencies between primary and metastatic
sites indicates that the aberrations in the PI3K pathway assayed are not obligatory for the
metastatic process, did not drive the metastatic process and are not selected during the
metastatic process. There were also some cases in which we detected marked differences in
the percent of cells with PIK3CA mutations between primary and metastases indicative of
dominance of different clones in the primary and metastasis. The underlying mechanism and
clinical significance of these changes should be formally studied. However, it is clear that
this should be considered in the design and implementation of trials of PI3K pathway
targeted therapy.
Changes in receptor expression may either account for a true biological phenomenon or may
result from inconsistent measurement. It has been argued that changes in receptor expression
may occur at different time points of disease (molecular evolution), and possible reasons
include: change during tumor progression as a consequence of genetic instabiilty or clonal
selection (23), intratumoral heterogeneity (24,25), selection by therapy or metastatic
process, and mutations induced by cellular exposure to systemic agents such as
chemotherapy or hormonal therapy, or targeted therapy. However, evidence derived from
transcriptional profiling suggests that the hard-wired characteristics of individual tumors do
not change by chance throughout the course of the disease. Weigelt et al. (26) showed that
gene expression profiles of metastases clustered closely to their corresponding primary
tumors, which may indicate that the metastatic capability may be an intrinsic feature of the
primary tumor. As an alternative hypothesis for this observation, the particular genomic
aberrations driving the tumor may only allow the tumor to explore a limited transcriptional
space and that processes regulating metastasis are not able to dominate the underlying
transcriptional pattern.
Further studies are needed to confirm our findings, and if they represent a true biological
discordance as discussed before or the limitations of marker development such as the poor
reproducibility of IHC, or preanalytic variables including variation in processing and
fixation of tumors, tumor hypoxia times, and tumor cellularity. However, it is important to
emphasize that the MassArray approach applied to assess DNA mutations is highly robust
and unlikely to demonstrated a significant false positive or negative rate and also to be able
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to detect relatively rare events in the tumor mass. As new targeted therapies are brought into
clinical trials using primary tumor signatures for patient selection may not represent the
signature status in the metastatic disease that is being treated and this may have significant
outcome implications. Indeed, it may be necessary to develop approaches to assess
predictive signatures present in metastatic disease to engender optimal outcomes. This could
be through repeat biopsies, novel molecular imaging technologies or potentially through
analysis of circulating DNA, microRNA or tumor cells. Identification of robust biomarkers
that can accurately assess driver aberrations and predict response to therapies, and that can
be used widely with low inter-laboratory variability is critical to successful delivery
personalized cancer therapy.
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Figure 1.
Proportion of primary tumor and metastases with PTEN loss and PIK3CA mutations (A and
C). Distribution of the changes in PTEN levels and PIK3CA mutation status from primary
tumor to metastases (B and C).
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Figure 2.
Immunohistochemical staining for PTEN in different cases of primary and metastatic
disease. A and B show stable positive and negative staining respectively. C and D show
changes in PTEN levels from absent to gain, and from present to loss respectively.
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Figure 3.
A representative case of a marked increase levels of PIK3CA mutation at PIK3CA_H1047R
from A primary tumor (17%) to B metastasis (76%).
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Table 2
PTEN Loss and PIK3CA Mutations by Breast Cancer Subtype
Primary Tumor Hormone Receptor- Positive (n=37) HER2-Positive (n=10) Triple Negative (n=4) Total (51)
PTEN Loss: 10/32 2/10 2/4 14/46 (30.4%)
PIK3CA Mutations: 15/34 3/9 1/4 19/47 (40.4%)
Both: 4/32 1/10 1/4 6/46 (13%)
Either or Both: 19/34 4/9 2/4 25/47 (53.2%)
Metastasis Hormone Receptor- positive (n=38) HER2-positive (n=12) Triple Negative (n=6) Total (56)
PTEN Loss: 10/34 2/12 1/6 13/52 (25%)
PIK3CA Mutations 15/34 4/11 2/5 21/50 (42%)
Both: 2/34 1/12 1/6 4/50 (8%)
Either or Both: 17/34 5/12 3/6 25/50 (50%)
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Table 4
Significant changes in the levels of PIK3CA mutations in the primary and metastatic tumors
Direction PIK3CA Mutation Level PIK3CA Mutation Level
Primary Tumor Metastases
Increase 12% 30%
Increase 17% 27%
Increase 17% 76%
Increase 9% 47%
Decrease 69% 24%
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